00:00
Speaker A
Time to round up some earnings here brought to you by Eco Lab.
00:03
Speaker A
Starting with AstraZeneca, company topping analyst estimates for sales and profits in its third quarter, driven by growth in its cancer and rare disease medicines.
00:12
Speaker A
AstraZeneca also announcing a one and a half billion dollar cost savings program to help free up resources to invest in its drug pipeline.
00:20
Speaker A
On to another drug maker, AbbVie also topping expectations thanks to higher sales for its immunology and neuroscience drugs.
00:29
Speaker A
The company also issuing higher than expected profit outlook and raising its quarterly dividend to $1.82 a share.
00:37
Speaker A
And finally, Kenvue appears to be on track with its turnaround plan as it prepares to acquire Kimberly Clark in a $40 billion deal.
00:46
Speaker A
The Tylenol maker just beat estimates on its top and bottom line, its self-care and essential health units both showing growth, while skin health and beauty declined in its third quarter.
